IMA Made on India campaign: IMA Jan Aushadhi Initiative

•  Ensuring availability of quality medicines at affordable prices to all, is a key objective of IMA.
•  India has a strong capability in producing quality branded and generic medicines in most of the therapeutic categories.
• Indian pharma industry has evolved from an mere Rs 1,500 crores industry in 1980 to a more than Rs 1,19,000 crores industry in 2012.
•  Indian drugs are reasonably priced, as compared to the prices of their equivalent medicines in most other countries.
• IMA is concerned that a large population of poor people in the country, find it difficult to afford the more expensive branded category of medicines.
• IMA endorses Jan Aushadhi Campaign which is run with the active participation of the CPSUs namely, IDPL, HAL, BPC. The central objective of the campaign is to make quality medicines available to the consumers at affordable prices
• IMA also invited its state branches to run Jan Aushadhi Stores. Recurring expenses on maintenance and running of the stores outside the government hospitals will have to be incurred by the branches. For this purpose, reasonable margins can be built up in the MRP of Jan Aushadhi Drugs.
•  The IMA- Jan Aushadhi initiative will make available quality drugs at affordable prices through dedicated stores selling generic medicines from standard Indian companies manufactured by BPPI ( Bureau of Pharma Public Sector Undertaking) which are available at lesser prices but are equivalent in quality and efficacy as expensive branded drugs.
•  Some comparative prices are: Ciprofloxacin 250 mg 10 tablets 12.89 Rs as against market prize of Rs 54.79; Ciprofloxacin 500 mg 10 tablets 24.99 Rs as against market prize of Rs 125.00; diclofenac 100 mg 10 tablets at Rs 420 as against market prize of Rs 60.40 Rs; cetrizine tablets 10 mg 10 tablets 2.75 Rs as against market prize of Rs 20 and tablet paracetamol 500 mg ten tablets 3 Rs as against market prose of Rs 9.40
•  BPPI Indian medicines with generic names are likely to be available in India by April in most of the chemist shops.
•  IMA doctors, are advised to write drugs with generic name in capital letter ( in bracket BPPI) so that they get drugs of good quality from recognized Indian companies.
•  For a quality cheaper drug BPPI will be the new brand.
•  Under BPPI, logo, drugs from Indian reputed companies will be available at affordable fixed prizes

Drugs Licence for IMA Pharmacy

Prescribing of Generic Medicines (Under Gadget Notification)

MCI has proposed for amendments in Chapter-1-B – Duties and responsibilities of the Physician in general, Clause 1.5 – Use of Generic names of drugs :

“Every physician should, prescribe drugs with generic names legible and in capital letters and he/she shall ensure that there is a rational prescription and use of drugs”.

Secretary (HFW) has proposed the following :-

“Every physician should, prescribe drugs with generic names legible and preferably in capital letters and he/she shall ensure that there is a rational prescription and use of drugs”.